Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plaster for topical use containing heparin and diclofenac

a technology of diclofenac and heparin, which is applied in the field of topical use of heparin and diclofenac, and can solve the problems of greasy residue on the skin, inability to achieve uniform dosing of active ingredients, and considerable inconvenien

Inactive Publication Date: 2003-10-30
DONATI ELISABETTA +1
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Though remarkably effective, these creams involve a number of drawbacks.
In addition, the creams, the application of which involves first spreading the cream, and subsequently rubbing or gentle massaging on the area affected, do not enable uniform dosing of the active principle from one application to the next.
In addition, with this type of formulation it is not possible to control in any way the release of active principle; consequently, these formulations must be applied on the area affected at least twice a day, with considerable inconvenience, in that they necessarily leave greasy residue on the skin.
This type of plaster represents an alternative system to oral administration of diclofenac, and administration which, as is known, presents considerable undesirable effects at the gastric level.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plaster for topical use containing heparin and diclofenac
  • Plaster for topical use containing heparin and diclofenac

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] In the plaster according to the present invention, diclofenac is generally present in the form of a pharmaceutically acceptable salt, and preferably it is a salt with a heterocyclic amine of general formula: 1

[0014] where m is 0 or1.

[0015] According to a particularly preferred embodiment, the heterocyclic amine is N-hydroxyethyl pyrrolidine (epolamine).

[0016] The diclofenac salt is contained in the plaster according to the present invention in concentrations generally ranging from 0.1 to 5 wt %, preferably in concentrations of between 0.3 and 3 wt % with respect to the total weight of the composition used for the preparation of the hydrogel matrix.

[0017] According to a particularly preferred embodiment, the concentration of the diclofenac salt is 1.3 wt % with respect to the total weight of the composition used for the preparation of the hydrogel matrix.

[0018] When the plaster according to the present invention contains a heparinoid, the latter preferably presents a molecular...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
adhesiveaaaaaaaaaa
concentrationsaaaaaaaaaa
total weightaaaaaaaaaa
Login to View More

Abstract

Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

Description

SCOPE OF INVENTION[0001] Plaster for topical use having an analgesic activity and being able to re-absorb haematomas, containing diclofenac in association with heparin or a heparinoid.STATE OF THE ART[0002] Known and available on the market are creams for topical use with a base of heparinoids, possibly in association with hyaluronidase, for re-absorption of haematomas and ecchymoses.[0003] Though remarkably effective, these creams involve a number of drawbacks. In fact, they do not present a more specific analgesic activity, which would be particularly necessary in the case of serious ecchymoses.[0004] In addition, the creams, the application of which involves first spreading the cream, and subsequently rubbing or gentle massaging on the area affected, do not enable uniform dosing of the active principle from one application to the next.[0005] In addition, with this type of formulation it is not possible to control in any way the release of active principle; consequently, these for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/70A61K31/727A61L15/44A61P17/02
CPCA61K9/7038A61K9/7053A61K31/727A61L15/44A61L2300/802A61L2300/41A61L2300/42A61L2300/45A61L2300/402A61P17/02
Inventor DONATI, ELISABETTARAPAPORT, IRINA
Owner DONATI ELISABETTA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com